Edition:
United Kingdom

Tracon Pharmaceuticals announces positive results from phase 1 trial of TRC102, Fludara


Monday, 13 Nov 2017 

Nov 13 (Reuters) - Tracon Pharmaceuticals Inc ::Tracon Pharmaceuticals announces positive results from phase 1 trial of trc102 and fludara® in patients with advanced hematologic malignancy published in oncotarget.Tracon Pharmaceuticals -‍in trial, 4 of 17 patients experienced partial response to treatment, eight additional patients (8/17, 47%) had stable disease​.Tracon Pharmaceuticals -‍in trial, combination of trc102,fludara produced evidence of tumor DNA damage that appeared to correlate with antitumor activity​. 

Company Quote

1.1
 --
12 Dec 2018